TYBOURNE CAPITAL MANAGEMENT (HK) LTD

Est. AUM

$30.93B

13F long equity, this entity only

Positions

Period

Sep 2025 (Q3)

SEC EDGAR

Sep 2025 (Q3)

#	Issuer	Class	Value	Shares	% Portfolio	Discretion
1	TAYSHA GENE THERAPIES INC (TSHA US)	COM SHS	$12.10B	3700000	39.11%	SOLE
2	FORTE BIOSCIENCES INC (FBRX US)	COM NEW	$11.80B	786647	38.15%	SOLE
3	ALUMIS INC (ALMS US)	COM	$5.58B	1399250	18.05%	SOLE
4	ZENTALIS PHARMACEUTICALS INC (ZNTL US)	COM	$1.45B	961486	4.69%	SOLE

Values in USD (reported in $thousands on 13F). Source: SEC EDGAR.